nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—multiple sclerosis—amyotrophic lateral sclerosis	0.676	1	CtDrD
Methotrexate—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.149	1	CbGbCtD
Methotrexate—Motor dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00567	0.0665	CcSEcCtD
Methotrexate—ATIC—forelimb—amyotrophic lateral sclerosis	0.00324	0.0725	CbGeAlD
Methotrexate—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.00315	0.037	CcSEcCtD
Methotrexate—ATIC—hindlimb—amyotrophic lateral sclerosis	0.00292	0.0652	CbGeAlD
Methotrexate—SLC19A1—tongue—amyotrophic lateral sclerosis	0.00269	0.0601	CbGeAlD
Methotrexate—ATIC—appendage—amyotrophic lateral sclerosis	0.0025	0.0559	CbGeAlD
Methotrexate—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0259	CcSEcCtD
Methotrexate—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0259	CcSEcCtD
Methotrexate—Dementia—Riluzole—amyotrophic lateral sclerosis	0.002	0.0235	CcSEcCtD
Methotrexate—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0227	CcSEcCtD
Methotrexate—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0223	CcSEcCtD
Methotrexate—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00168	0.0197	CcSEcCtD
Methotrexate—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0172	CcSEcCtD
Methotrexate—ABCC11—embryo—amyotrophic lateral sclerosis	0.00141	0.0315	CbGeAlD
Methotrexate—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0159	CcSEcCtD
Methotrexate—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0153	CcSEcCtD
Methotrexate—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00129	0.0152	CcSEcCtD
Methotrexate—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00128	0.015	CcSEcCtD
Methotrexate—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0144	CcSEcCtD
Methotrexate—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00118	0.0139	CcSEcCtD
Methotrexate—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0136	CcSEcCtD
Methotrexate—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0136	CcSEcCtD
Methotrexate—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0136	CcSEcCtD
Methotrexate—Stupor—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0129	CcSEcCtD
Methotrexate—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0126	CcSEcCtD
Methotrexate—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0124	CcSEcCtD
Methotrexate—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0122	CcSEcCtD
Methotrexate—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.000999	0.0117	CcSEcCtD
Methotrexate—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00097	0.0114	CcSEcCtD
Methotrexate—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.000916	0.0108	CcSEcCtD
Methotrexate—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00091	0.0107	CcSEcCtD
Methotrexate—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.000892	0.0105	CcSEcCtD
Methotrexate—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.000869	0.0102	CcSEcCtD
Methotrexate—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.000869	0.0102	CcSEcCtD
Methotrexate—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.000837	0.00982	CcSEcCtD
Methotrexate—ATIC—embryo—amyotrophic lateral sclerosis	0.000831	0.0186	CbGeAlD
Methotrexate—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.000822	0.00965	CcSEcCtD
Methotrexate—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000803	0.00942	CcSEcCtD
Methotrexate—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000794	0.00932	CcSEcCtD
Methotrexate—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000772	0.00906	CcSEcCtD
Methotrexate—ATIC—brainstem—amyotrophic lateral sclerosis	0.000761	0.017	CbGeAlD
Methotrexate—Coma—Riluzole—amyotrophic lateral sclerosis	0.000751	0.00882	CcSEcCtD
Methotrexate—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00872	CcSEcCtD
Methotrexate—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00872	CcSEcCtD
Methotrexate—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00859	CcSEcCtD
Methotrexate—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.000713	0.00837	CcSEcCtD
Methotrexate—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000699	0.00821	CcSEcCtD
Methotrexate—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00805	CcSEcCtD
Methotrexate—FOLR1—central nervous system—amyotrophic lateral sclerosis	0.00068	0.0152	CbGeAlD
Methotrexate—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00798	CcSEcCtD
Methotrexate—FOLR1—cerebellum—amyotrophic lateral sclerosis	0.000664	0.0148	CbGeAlD
Methotrexate—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000632	0.00742	CcSEcCtD
Methotrexate—GGH—medulla oblongata—amyotrophic lateral sclerosis	0.000624	0.014	CbGeAlD
Methotrexate—SLC19A1—nervous system—amyotrophic lateral sclerosis	0.000619	0.0138	CbGeAlD
Methotrexate—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000616	0.00724	CcSEcCtD
Methotrexate—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000597	0.007	CcSEcCtD
Methotrexate—SLC19A1—central nervous system—amyotrophic lateral sclerosis	0.000596	0.0133	CbGeAlD
Methotrexate—SLC19A1—cerebellum—amyotrophic lateral sclerosis	0.000583	0.013	CbGeAlD
Methotrexate—SLC46A1—spinal cord—amyotrophic lateral sclerosis	0.000566	0.0126	CbGeAlD
Methotrexate—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000565	0.00663	CcSEcCtD
Methotrexate—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000561	0.00658	CcSEcCtD
Methotrexate—DHFR—embryo—amyotrophic lateral sclerosis	0.000558	0.0125	CbGeAlD
Methotrexate—GGH—spinal cord—amyotrophic lateral sclerosis	0.000557	0.0124	CbGeAlD
Methotrexate—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000551	0.00647	CcSEcCtD
Methotrexate—FPGS—medulla oblongata—amyotrophic lateral sclerosis	0.000549	0.0123	CbGeAlD
Methotrexate—FOLR1—brain—amyotrophic lateral sclerosis	0.00054	0.0121	CbGeAlD
Methotrexate—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000539	0.00633	CcSEcCtD
Methotrexate—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000516	0.00605	CcSEcCtD
Methotrexate—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000506	0.00593	CcSEcCtD
Methotrexate—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000494	0.0058	CcSEcCtD
Methotrexate—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00049	0.00575	CcSEcCtD
Methotrexate—FPGS—spinal cord—amyotrophic lateral sclerosis	0.000489	0.0109	CbGeAlD
Methotrexate—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000482	0.00566	CcSEcCtD
Methotrexate—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000482	0.00566	CcSEcCtD
Methotrexate—SLC46A1—nervous system—amyotrophic lateral sclerosis	0.000477	0.0107	CbGeAlD
Methotrexate—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00557	CcSEcCtD
Methotrexate—ATIC—spinal cord—amyotrophic lateral sclerosis	0.000473	0.0106	CbGeAlD
Methotrexate—SLC19A1—brain—amyotrophic lateral sclerosis	0.000473	0.0106	CbGeAlD
Methotrexate—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00552	CcSEcCtD
Methotrexate—GGH—nervous system—amyotrophic lateral sclerosis	0.000469	0.0105	CbGeAlD
Methotrexate—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000462	0.00543	CcSEcCtD
Methotrexate—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00046	0.0054	CcSEcCtD
Methotrexate—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00046	0.0054	CcSEcCtD
Methotrexate—SLC46A1—central nervous system—amyotrophic lateral sclerosis	0.000459	0.0103	CbGeAlD
Methotrexate—Depression—Riluzole—amyotrophic lateral sclerosis	0.000458	0.00538	CcSEcCtD
Methotrexate—GGH—central nervous system—amyotrophic lateral sclerosis	0.000452	0.0101	CbGeAlD
Methotrexate—SLC46A1—cerebellum—amyotrophic lateral sclerosis	0.000449	0.01	CbGeAlD
Methotrexate—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00526	CcSEcCtD
Methotrexate—GGH—cerebellum—amyotrophic lateral sclerosis	0.000441	0.00987	CbGeAlD
Methotrexate—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000441	0.00517	CcSEcCtD
Methotrexate—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000438	0.00515	CcSEcCtD
Methotrexate—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000435	0.0051	CcSEcCtD
Methotrexate—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00509	CcSEcCtD
Methotrexate—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000429	0.00504	CcSEcCtD
Methotrexate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000415	0.00487	CcSEcCtD
Methotrexate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00484	CcSEcCtD
Methotrexate—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00484	CcSEcCtD
Methotrexate—FPGS—nervous system—amyotrophic lateral sclerosis	0.000412	0.00922	CbGeAlD
Methotrexate—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00481	CcSEcCtD
Methotrexate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000408	0.00478	CcSEcCtD
Methotrexate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000405	0.00475	CcSEcCtD
Methotrexate—ATIC—nervous system—amyotrophic lateral sclerosis	0.000399	0.00892	CbGeAlD
Methotrexate—FPGS—central nervous system—amyotrophic lateral sclerosis	0.000397	0.00888	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—amyotrophic lateral sclerosis	0.000394	0.0088	CbGeAlD
Methotrexate—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00039	0.00458	CcSEcCtD
Methotrexate—SLCO3A1—medulla oblongata—amyotrophic lateral sclerosis	0.000388	0.00868	CbGeAlD
Methotrexate—FPGS—cerebellum—amyotrophic lateral sclerosis	0.000388	0.00868	CbGeAlD
Methotrexate—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000386	0.00453	CcSEcCtD
Methotrexate—ATIC—central nervous system—amyotrophic lateral sclerosis	0.000384	0.00858	CbGeAlD
Methotrexate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000383	0.0045	CcSEcCtD
Methotrexate—ATIC—cerebellum—amyotrophic lateral sclerosis	0.000375	0.00839	CbGeAlD
Methotrexate—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000374	0.0044	CcSEcCtD
Methotrexate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00438	CcSEcCtD
Methotrexate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00437	CcSEcCtD
Methotrexate—Chills—Riluzole—amyotrophic lateral sclerosis	0.00037	0.00435	CcSEcCtD
Methotrexate—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000365	0.00428	CcSEcCtD
Methotrexate—SLC46A1—brain—amyotrophic lateral sclerosis	0.000364	0.00815	CbGeAlD
Methotrexate—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000362	0.00424	CcSEcCtD
Methotrexate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000359	0.00422	CcSEcCtD
Methotrexate—GGH—brain—amyotrophic lateral sclerosis	0.000359	0.00802	CbGeAlD
Methotrexate—DHFR—medulla oblongata—amyotrophic lateral sclerosis	0.000356	0.00797	CbGeAlD
Methotrexate—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00413	CcSEcCtD
Methotrexate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000348	0.00408	CcSEcCtD
Methotrexate—SLCO3A1—spinal cord—amyotrophic lateral sclerosis	0.000346	0.00774	CbGeAlD
Methotrexate—PGD—medulla oblongata—amyotrophic lateral sclerosis	0.000343	0.00766	CbGeAlD
Methotrexate—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000333	0.00391	CcSEcCtD
Methotrexate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000332	0.0039	CcSEcCtD
Methotrexate—SLCO1C1—nervous system—amyotrophic lateral sclerosis	0.000332	0.00741	CbGeAlD
Methotrexate—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000324	0.0038	CcSEcCtD
Methotrexate—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00379	CcSEcCtD
Methotrexate—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000322	0.00378	CcSEcCtD
Methotrexate—SLC16A1—medulla oblongata—amyotrophic lateral sclerosis	0.00032	0.00715	CbGeAlD
Methotrexate—SLCO1C1—central nervous system—amyotrophic lateral sclerosis	0.000319	0.00714	CbGeAlD
Methotrexate—DHFR—spinal cord—amyotrophic lateral sclerosis	0.000318	0.00711	CbGeAlD
Methotrexate—FPGS—brain—amyotrophic lateral sclerosis	0.000315	0.00705	CbGeAlD
Methotrexate—Cough—Riluzole—amyotrophic lateral sclerosis	0.000314	0.00368	CcSEcCtD
Methotrexate—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000311	0.00365	CcSEcCtD
Methotrexate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00359	CcSEcCtD
Methotrexate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00359	CcSEcCtD
Methotrexate—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00359	CcSEcCtD
Methotrexate—PGD—spinal cord—amyotrophic lateral sclerosis	0.000306	0.00683	CbGeAlD
Methotrexate—ATIC—brain—amyotrophic lateral sclerosis	0.000305	0.00682	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000304	0.00357	CcSEcCtD
Methotrexate—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000302	0.00355	CcSEcCtD
Methotrexate—MTHFR—nervous system—amyotrophic lateral sclerosis	0.000296	0.00663	CbGeAlD
Methotrexate—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000296	0.00347	CcSEcCtD
Methotrexate—ABCC10—medulla oblongata—amyotrophic lateral sclerosis	0.000294	0.00657	CbGeAlD
Methotrexate—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000293	0.00344	CcSEcCtD
Methotrexate—SLCO3A1—nervous system—amyotrophic lateral sclerosis	0.000292	0.00652	CbGeAlD
Methotrexate—Infection—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00342	CcSEcCtD
Methotrexate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000288	0.00338	CcSEcCtD
Methotrexate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000287	0.00337	CcSEcCtD
Methotrexate—MTHFR—central nervous system—amyotrophic lateral sclerosis	0.000285	0.00638	CbGeAlD
Methotrexate—SLC16A1—spinal cord—amyotrophic lateral sclerosis	0.000285	0.00638	CbGeAlD
Methotrexate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000285	0.00334	CcSEcCtD
Methotrexate—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00333	CcSEcCtD
Methotrexate—SLCO3A1—central nervous system—amyotrophic lateral sclerosis	0.000281	0.00628	CbGeAlD
Methotrexate—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00028	0.00328	CcSEcCtD
Methotrexate—MTHFR—cerebellum—amyotrophic lateral sclerosis	0.000279	0.00624	CbGeAlD
Methotrexate—SLCO3A1—cerebellum—amyotrophic lateral sclerosis	0.000274	0.00614	CbGeAlD
Methotrexate—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000274	0.00322	CcSEcCtD
Methotrexate—TYMS—nervous system—amyotrophic lateral sclerosis	0.000271	0.00605	CbGeAlD
Methotrexate—DHFR—nervous system—amyotrophic lateral sclerosis	0.000268	0.00599	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000267	0.00314	CcSEcCtD
Methotrexate—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000265	0.00311	CcSEcCtD
Methotrexate—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000263	0.00309	CcSEcCtD
Methotrexate—ABCC10—spinal cord—amyotrophic lateral sclerosis	0.000262	0.00586	CbGeAlD
Methotrexate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00307	CcSEcCtD
Methotrexate—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00306	CcSEcCtD
Methotrexate—TYMS—central nervous system—amyotrophic lateral sclerosis	0.00026	0.00582	CbGeAlD
Methotrexate—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000258	0.00303	CcSEcCtD
Methotrexate—DHFR—central nervous system—amyotrophic lateral sclerosis	0.000258	0.00576	CbGeAlD
Methotrexate—PGD—nervous system—amyotrophic lateral sclerosis	0.000257	0.00576	CbGeAlD
Methotrexate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000255	0.00299	CcSEcCtD
Methotrexate—TYMS—cerebellum—amyotrophic lateral sclerosis	0.000255	0.00569	CbGeAlD
Methotrexate—SLCO1C1—brain—amyotrophic lateral sclerosis	0.000253	0.00567	CbGeAlD
Methotrexate—SLCO1A2—medulla oblongata—amyotrophic lateral sclerosis	0.000253	0.00566	CbGeAlD
Methotrexate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000253	0.00297	CcSEcCtD
Methotrexate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000253	0.00297	CcSEcCtD
Methotrexate—DHFR—cerebellum—amyotrophic lateral sclerosis	0.000252	0.00563	CbGeAlD
Methotrexate—Pain—Riluzole—amyotrophic lateral sclerosis	0.000251	0.00294	CcSEcCtD
Methotrexate—PGD—central nervous system—amyotrophic lateral sclerosis	0.000248	0.00554	CbGeAlD
Methotrexate—PGD—cerebellum—amyotrophic lateral sclerosis	0.000242	0.00542	CbGeAlD
Methotrexate—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000242	0.00284	CcSEcCtD
Methotrexate—SLC16A1—nervous system—amyotrophic lateral sclerosis	0.00024	0.00537	CbGeAlD
Methotrexate—SLC22A7—brain—amyotrophic lateral sclerosis	0.00024	0.00537	CbGeAlD
Methotrexate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00024	0.00281	CcSEcCtD
Methotrexate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000233	0.00273	CcSEcCtD
Methotrexate—SLC22A6—brain—amyotrophic lateral sclerosis	0.000232	0.00519	CbGeAlD
Methotrexate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000232	0.00272	CcSEcCtD
Methotrexate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000232	0.00272	CcSEcCtD
Methotrexate—SLC16A1—central nervous system—amyotrophic lateral sclerosis	0.000231	0.00517	CbGeAlD
Methotrexate—MTHFR—brain—amyotrophic lateral sclerosis	0.000227	0.00507	CbGeAlD
Methotrexate—SLC16A1—cerebellum—amyotrophic lateral sclerosis	0.000226	0.00506	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—amyotrophic lateral sclerosis	0.000226	0.00505	CbGeAlD
Methotrexate—SLCO3A1—brain—amyotrophic lateral sclerosis	0.000223	0.00498	CbGeAlD
Methotrexate—ABCC3—nervous system—amyotrophic lateral sclerosis	0.000222	0.00496	CbGeAlD
Methotrexate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000216	0.00254	CcSEcCtD
Methotrexate—ABCC3—central nervous system—amyotrophic lateral sclerosis	0.000214	0.00478	CbGeAlD
Methotrexate—AOX1—cerebellum—amyotrophic lateral sclerosis	0.000213	0.00477	CbGeAlD
Methotrexate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00021	0.00247	CcSEcCtD
Methotrexate—ABCC10—cerebellum—amyotrophic lateral sclerosis	0.000208	0.00464	CbGeAlD
Methotrexate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000207	0.00244	CcSEcCtD
Methotrexate—TYMS—brain—amyotrophic lateral sclerosis	0.000207	0.00462	CbGeAlD
Methotrexate—DHFR—brain—amyotrophic lateral sclerosis	0.000205	0.00458	CbGeAlD
Methotrexate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000201	0.00235	CcSEcCtD
Methotrexate—PGD—brain—amyotrophic lateral sclerosis	0.000197	0.0044	CbGeAlD
Methotrexate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000194	0.00228	CcSEcCtD
Methotrexate—SLCO1A2—nervous system—amyotrophic lateral sclerosis	0.00019	0.00425	CbGeAlD
Methotrexate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000186	0.00219	CcSEcCtD
Methotrexate—Rash—Riluzole—amyotrophic lateral sclerosis	0.000185	0.00217	CcSEcCtD
Methotrexate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000185	0.00217	CcSEcCtD
Methotrexate—SLC16A1—brain—amyotrophic lateral sclerosis	0.000184	0.00411	CbGeAlD
Methotrexate—Headache—Riluzole—amyotrophic lateral sclerosis	0.000184	0.00216	CcSEcCtD
Methotrexate—SLCO1A2—central nervous system—amyotrophic lateral sclerosis	0.000183	0.0041	CbGeAlD
Methotrexate—ABCC4—nervous system—amyotrophic lateral sclerosis	0.000183	0.00409	CbGeAlD
Methotrexate—SLC22A8—nervous system—amyotrophic lateral sclerosis	0.000182	0.00406	CbGeAlD
Methotrexate—SLCO1A2—cerebellum—amyotrophic lateral sclerosis	0.000179	0.004	CbGeAlD
Methotrexate—ABCC4—central nervous system—amyotrophic lateral sclerosis	0.000176	0.00394	CbGeAlD
Methotrexate—SLC22A8—central nervous system—amyotrophic lateral sclerosis	0.000175	0.00391	CbGeAlD
Methotrexate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000174	0.00204	CcSEcCtD
Methotrexate—AOX1—brain—amyotrophic lateral sclerosis	0.000173	0.00388	CbGeAlD
Methotrexate—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000172	0.00385	CbGeAlD
Methotrexate—ABCC3—brain—amyotrophic lateral sclerosis	0.00017	0.00379	CbGeAlD
Methotrexate—ABCC10—brain—amyotrophic lateral sclerosis	0.000169	0.00377	CbGeAlD
Methotrexate—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000153	0.00343	CbGeAlD
Methotrexate—ABCC1—cerebellum—amyotrophic lateral sclerosis	0.000147	0.00328	CbGeAlD
Methotrexate—SLCO1A2—brain—amyotrophic lateral sclerosis	0.000145	0.00325	CbGeAlD
Methotrexate—ALB—brain—amyotrophic lateral sclerosis	0.000145	0.00323	CbGeAlD
Methotrexate—ABCC4—brain—amyotrophic lateral sclerosis	0.00014	0.00313	CbGeAlD
Methotrexate—SLC22A8—brain—amyotrophic lateral sclerosis	0.000139	0.0031	CbGeAlD
Methotrexate—ABCB1—embryo—amyotrophic lateral sclerosis	0.000133	0.00297	CbGeAlD
Methotrexate—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000122	0.00272	CbGeAlD
Methotrexate—ABCC1—brain—amyotrophic lateral sclerosis	0.000119	0.00267	CbGeAlD
Methotrexate—ABCG2—brain—amyotrophic lateral sclerosis	9.88e-05	0.00221	CbGeAlD
Methotrexate—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	8.48e-05	0.0019	CbGeAlD
Methotrexate—ABCB1—spinal cord—amyotrophic lateral sclerosis	7.57e-05	0.00169	CbGeAlD
Methotrexate—ABCB1—nervous system—amyotrophic lateral sclerosis	6.38e-05	0.00143	CbGeAlD
Methotrexate—ABCB1—central nervous system—amyotrophic lateral sclerosis	6.14e-05	0.00137	CbGeAlD
Methotrexate—ABCB1—cerebellum—amyotrophic lateral sclerosis	6e-05	0.00134	CbGeAlD
Methotrexate—ABCB1—brain—amyotrophic lateral sclerosis	4.87e-05	0.00109	CbGeAlD
Methotrexate—SLCO1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.63e-05	0.000577	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.62e-05	0.000575	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.62e-05	0.000575	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.62e-05	0.000575	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.61e-05	0.000572	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.61e-05	0.000571	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.61e-05	0.000571	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	2.6e-05	0.00057	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.6e-05	0.00057	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.57e-05	0.000564	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.57e-05	0.000563	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.57e-05	0.000563	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ERBB4—amyotrophic lateral sclerosis	2.54e-05	0.000557	CbGpPWpGaD
Methotrexate—FPGS—Disease—APOE—amyotrophic lateral sclerosis	2.52e-05	0.000553	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.52e-05	0.000552	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PLB1—amyotrophic lateral sclerosis	2.5e-05	0.000548	CbGpPWpGaD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	2.5e-05	0.000548	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	2.5e-05	0.000548	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.49e-05	0.000547	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.49e-05	0.000547	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—APOE—amyotrophic lateral sclerosis	2.49e-05	0.000545	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CST3—amyotrophic lateral sclerosis	2.46e-05	0.00054	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CHAT—amyotrophic lateral sclerosis	2.44e-05	0.000536	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.44e-05	0.000536	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	2.42e-05	0.00053	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	0.000528	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.41e-05	0.000528	CbGpPWpGaD
Methotrexate—AOX1—Disease—CST3—amyotrophic lateral sclerosis	2.41e-05	0.000528	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.39e-05	0.000524	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.39e-05	0.000523	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.38e-05	0.000522	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.38e-05	0.000521	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.37e-05	0.00052	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.37e-05	0.000519	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.37e-05	0.000519	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.34e-05	0.000513	CbGpPWpGaD
Methotrexate—PGD—Disease—ERBB4—amyotrophic lateral sclerosis	2.32e-05	0.00051	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.31e-05	0.000506	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.31e-05	0.000506	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GSR—amyotrophic lateral sclerosis	2.31e-05	0.000506	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	2.3e-05	0.000505	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PLB1—amyotrophic lateral sclerosis	2.29e-05	0.000503	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	2.28e-05	0.0005	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.25e-05	0.000493	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.24e-05	0.00049	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.22e-05	0.000487	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.22e-05	0.000486	CbGpPWpGaD
Methotrexate—DHFR—Disease—CST3—amyotrophic lateral sclerosis	2.19e-05	0.00048	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.18e-05	0.000477	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CHAT—amyotrophic lateral sclerosis	2.17e-05	0.000476	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CHMP2B—amyotrophic lateral sclerosis	2.14e-05	0.00047	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—DAO—amyotrophic lateral sclerosis	2.14e-05	0.000469	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GSR—amyotrophic lateral sclerosis	2.12e-05	0.000464	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—APOE—amyotrophic lateral sclerosis	2.11e-05	0.000463	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—APOE—amyotrophic lateral sclerosis	2.11e-05	0.000463	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	2.08e-05	0.000457	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.08e-05	0.000457	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PLB1—amyotrophic lateral sclerosis	2.07e-05	0.000454	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.06e-05	0.000451	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—DAO—amyotrophic lateral sclerosis	2.03e-05	0.000446	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—PTGS2—amyotrophic lateral sclerosis	2.03e-05	0.000446	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SOD1—amyotrophic lateral sclerosis	2e-05	0.000439	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2e-05	0.000439	CbGpPWpGaD
Methotrexate—PGD—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.99e-05	0.000437	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.98e-05	0.000434	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.98e-05	0.000434	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—APOE—amyotrophic lateral sclerosis	1.97e-05	0.000431	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PLB1—amyotrophic lateral sclerosis	1.94e-05	0.000425	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	1.94e-05	0.000425	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	1.93e-05	0.000423	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.93e-05	0.000423	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSR—amyotrophic lateral sclerosis	1.91e-05	0.000419	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CHAT—amyotrophic lateral sclerosis	1.9e-05	0.000416	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	1.88e-05	0.000413	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	1.88e-05	0.000411	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	1.86e-05	0.000407	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.83e-05	0.000401	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.8e-05	0.000395	CbGpPWpGaD
Methotrexate—PGD—Disease—APOE—amyotrophic lateral sclerosis	1.8e-05	0.000394	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	1.8e-05	0.000394	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CASP9—amyotrophic lateral sclerosis	1.79e-05	0.000393	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	1.76e-05	0.000386	CbGpPWpGaD
Methotrexate—AOX1—Disease—CASP9—amyotrophic lateral sclerosis	1.75e-05	0.000384	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	0.000381	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CHAT—amyotrophic lateral sclerosis	1.74e-05	0.000381	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTGS2—amyotrophic lateral sclerosis	1.73e-05	0.000379	CbGpPWpGaD
Methotrexate—ABCC1—Disease—VCP—amyotrophic lateral sclerosis	1.73e-05	0.000378	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.7e-05	0.000373	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.69e-05	0.00037	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.68e-05	0.000367	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.66e-05	0.000365	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	1.65e-05	0.000361	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.65e-05	0.000361	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.64e-05	0.000359	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	1.63e-05	0.000357	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.62e-05	0.000356	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	1.62e-05	0.000356	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	1.61e-05	0.000354	CbGpPWpGaD
Methotrexate—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	1.61e-05	0.000352	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	1.61e-05	0.000352	CbGpPWpGaD
Methotrexate—DHFR—Disease—CASP9—amyotrophic lateral sclerosis	1.59e-05	0.000349	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.59e-05	0.000348	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	1.58e-05	0.000346	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	1.58e-05	0.000346	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CHAT—amyotrophic lateral sclerosis	1.57e-05	0.000344	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	1.55e-05	0.000341	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.55e-05	0.000339	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.54e-05	0.000338	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.53e-05	0.000336	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.52e-05	0.000332	CbGpPWpGaD
Methotrexate—PGD—Metabolism—APOE—amyotrophic lateral sclerosis	1.51e-05	0.00033	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	1.5e-05	0.00033	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.5e-05	0.000329	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB4—amyotrophic lateral sclerosis	1.5e-05	0.000328	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSR—amyotrophic lateral sclerosis	1.5e-05	0.000328	CbGpPWpGaD
Methotrexate—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	1.47e-05	0.000322	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.47e-05	0.000322	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.45e-05	0.000317	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.45e-05	0.000317	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.43e-05	0.000314	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.43e-05	0.000313	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.43e-05	0.000312	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.43e-05	0.000312	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSR—amyotrophic lateral sclerosis	1.42e-05	0.000312	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	1.41e-05	0.000309	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	1.41e-05	0.000309	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	1.4e-05	0.000306	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	1.39e-05	0.000305	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.37e-05	0.0003	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.37e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	0.000299	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.36e-05	0.000299	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—amyotrophic lateral sclerosis	1.35e-05	0.000295	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	1.32e-05	0.000289	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.31e-05	0.000288	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.3e-05	0.000284	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.29e-05	0.000282	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	1.29e-05	0.000282	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.28e-05	0.000281	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.27e-05	0.000278	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.25e-05	0.000274	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.25e-05	0.000274	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.25e-05	0.000273	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CST3—amyotrophic lateral sclerosis	1.24e-05	0.000272	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—amyotrophic lateral sclerosis	1.23e-05	0.00027	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.23e-05	0.00027	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.22e-05	0.000268	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	0.000265	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.2e-05	0.000263	CbGpPWpGaD
Methotrexate—MTHFR—Disease—APOE—amyotrophic lateral sclerosis	1.19e-05	0.00026	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.18e-05	0.000259	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.17e-05	0.000256	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.17e-05	0.000256	CbGpPWpGaD
Methotrexate—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	1.16e-05	0.000255	CbGpPWpGaD
Methotrexate—AOX1—Disease—APOE—amyotrophic lateral sclerosis	1.16e-05	0.000254	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.13e-05	0.000247	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.13e-05	0.000247	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.12e-05	0.000246	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.11e-05	0.000244	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000238	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.08e-05	0.000237	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.07e-05	0.000235	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	1.07e-05	0.000235	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.07e-05	0.000235	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.07e-05	0.000234	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.06e-05	0.000233	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.06e-05	0.000232	CbGpPWpGaD
Methotrexate—DHFR—Disease—APOE—amyotrophic lateral sclerosis	1.05e-05	0.000231	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.03e-05	0.000226	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.02e-05	0.000223	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.02e-05	0.000223	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—APOE—amyotrophic lateral sclerosis	9.93e-06	0.000218	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.81e-06	0.000215	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.77e-06	0.000214	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—APOE—amyotrophic lateral sclerosis	9.7e-06	0.000213	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.36e-06	0.000205	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.35e-06	0.000205	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	9.07e-06	0.000199	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CASP9—amyotrophic lateral sclerosis	9.01e-06	0.000198	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—APOE—amyotrophic lateral sclerosis	8.83e-06	0.000194	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	8.81e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.76e-06	0.000192	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.59e-06	0.000188	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.54e-06	0.000187	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.43e-06	0.000185	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—amyotrophic lateral sclerosis	8.38e-06	0.000184	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	8.13e-06	0.000178	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.13e-06	0.000178	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	8.13e-06	0.000178	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—amyotrophic lateral sclerosis	8.13e-06	0.000178	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—amyotrophic lateral sclerosis	8.09e-06	0.000177	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—APOE—amyotrophic lateral sclerosis	8.04e-06	0.000176	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.98e-06	0.000175	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—amyotrophic lateral sclerosis	7.94e-06	0.000174	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.75e-06	0.00017	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	7.72e-06	0.000169	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB4—amyotrophic lateral sclerosis	7.71e-06	0.000169	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—APOE—amyotrophic lateral sclerosis	7.7e-06	0.000169	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.69e-06	0.000169	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.4e-06	0.000162	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.34e-06	0.000161	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—amyotrophic lateral sclerosis	7.31e-06	0.00016	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.3e-06	0.00016	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—amyotrophic lateral sclerosis	7.22e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.12e-06	0.000156	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—APOE—amyotrophic lateral sclerosis	7.07e-06	0.000155	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	7.01e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.9e-06	0.000151	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.81e-06	0.000149	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.75e-06	0.000148	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	6.68e-06	0.000146	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.65e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.61e-06	0.000145	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—APOE—amyotrophic lateral sclerosis	6.38e-06	0.00014	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.28e-06	0.000138	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.09e-06	0.000134	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.07e-06	0.000133	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.05e-06	0.000133	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—amyotrophic lateral sclerosis	6.03e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOE—amyotrophic lateral sclerosis	5.97e-06	0.000131	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.85e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.81e-06	0.000127	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.77e-06	0.000127	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOE—amyotrophic lateral sclerosis	5.55e-06	0.000122	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	5.53e-06	0.000121	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.51e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.34e-06	0.000117	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.28e-06	0.000116	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.21e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOE—amyotrophic lateral sclerosis	5e-06	0.00011	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.84e-06	0.000106	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOE—amyotrophic lateral sclerosis	4.75e-06	0.000104	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	4.4e-06	9.64e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.37e-06	9.58e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.17e-06	9.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—amyotrophic lateral sclerosis	4.09e-06	8.96e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.8e-06	8.34e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.61e-06	7.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.59e-06	7.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.42e-06	7.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.3e-06	7.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.25e-06	7.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.14e-06	6.89e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.01e-06	6.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.89e-06	6.33e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	2.73e-06	5.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	2.71e-06	5.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.38e-06	5.21e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.86e-06	4.07e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.63e-06	3.57e-05	CbGpPWpGaD
